Ticlopidine

TICIOPIDINE · pcr5332 · PCR 5332 · Ticlosin · Anagregal · Caudaline · TICLOPIDINE · PCR 5332|||Ticlid

Identifikatoren & physikalische Daten

CAS No.	55142-85-3
Summenformel	C14H14ClNS
Durchschnittliche Molmasse	263,8 g/mol
Monoisotopische Masse	263,05354813 g/mol
SMILES	Clc1ccccc1CN1CCc2sccc2C1
InChIKey	PHWBOXQYWZNQIN-UHFFFAOYSA-N
PubChem CID	5472
ChEMBL	CHEMBL833
ChEBI	CHEBI:9588
EC No.	259-498-5
DTXSID	DTXSID5023669

Chemische & physikalische Eigenschaften

XLogP	3,6
Polarare Oberfläche (TPSA)	31,5
H-Brücken-Donoren	0
H-Brücken-Akzeptoren	2
Frei drehbare Bindungen	2
Schwere Atome	17
Formalladung	0
Komplexität	261
Arzneimittel	Pharmaceuticals -> Listed in ZINC15
LogP (Verteilungskoeffizient)	2.93.46
Löslichkeit	Freely soluble2.19e-02 g/L1 [ug/mL] (The mean of the results at pH 7.4)Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
Schmelzpunkt	approx. 1 189°C210-212 °C
Physical Description	Solid
Collision Cross Section	156.8 Å² [M+H]+ [CCS Type: DTBuffer gas: N2Ionization: ESI+Dataset: TOXCASTSource Identifier: DTXSID80202141]153.84 Å² [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]
Siedepunkt	117-120 °C(Press: 0.5 Torr)
Dichte	1.273±0.06 g/cm3(Predicted)
Lagerbedingungen	2-8°C(protect from light)
Aggregatzustand	Solid
pKa (Säurekonstante)	7.10±0.20(Predicted)
Farbe	Off-White to Pale Yellow
CAS Datenbank	55142-85-3(CAS DataBase Reference)
NIST chemische Informationen	Thieno[3,2-c]pyridine, 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydro-(55142-85-3)
EPA chemische Informationen	Thieno[3,2-c]pyridine, 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydro- (55142-85-3)

Sicherheit & Vorschriften

Weitere Sicherheitsinformationen	IMAP assessments - Thieno[3,2-c]pyridine, 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydro-: Environment tier I assessment
Hepatotoxicity	Ticlopidine has been associated with serum enzyme elevations in approximately 4% of patients during therapy. These elevations are usually mild, asymptomatic and rarely require dose modification or stopping. Ticlopidine has also been associated with clinically apparent, acute liver injury. While these reactions are rare, more than 50 instances have been reported in the literature and some have been severe. The onset of symptoms is typically within 6 weeks (range 1 to 24 weeks) and marked by onset with fatigue, jaundice and itching. The usual pattern of liver enzyme elevations is cholestatic (~75%), but cases with mixed or hepatocellular enzyme elevations have also been described. Immunoallergic features such as fever, rash and eosinophilia can occur but are not common and, if present, are usually mild. Autoantibody formation is rare. Liver biopsy usually shows cholestatic hepatitis with mixed cellular infiltrates. Most cases are self-limited with recovery within 1 to 3 months, but isolated cases of prolonged jaundice or liver test abnormalities have been described, including at least one case of probable vanishing bile duct syndrome that eventually required liver transplantation. Ticlopidine therapy has also been associated with aplastic anemia and thrombotic thrombocytopenic purpura (TTP) that can be severe and lead to deaththese patients may also have accompanying cholestatic liver injury.
Drug Induced Liver Injury	Benchmark Dataset for the Liver Toxicity Knowledge Base (LTKB)ticlopidineTiclidAntithrombotics4most-DILI-concern
Alarmwort	Warnung
Gefahrenhinweise	Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code H315

Anwendungen & Verwendung

Verwenden

Ticlopidine suppresses aggregation of thrombocytes and possesses antiaggregant activity. It is believed that its action is connected to its effect on thrombocyte membranes and the reduction in quantity of released adenosine diphosphate and serotonin, which facilitate aggregation of thrombocytes. In wide-ranging clinical trials, ticlopidine presented a number of advantages compared to aspirin.